Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 46

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 46
---
-year anniversary of his start date, Mr. Carter would be required to repay the gross amount of the sign-on bonus to the Company. Mr. Brenner’s sign-on bonus is conditioned upon continuous service for two years from his start date, such that if his employment terminates for any reason other than the Company’s termination of his employment for cause or his resignation without good reason prior to the two-year anniversary of his start date, Mr. Brenner would be required to repay the after-tax amount of the sign-on bonus to the Company. |

| (2) | The dollar amounts in this column reflect the aggregate grant date fair value of RSUs granted during the indicated fiscal year computed in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Committee (“ASC”) Topic 718, excluding the effect of estimated forfeitures. The grant date fair value of each equity award is measured based on the closing price of our Class A common stock on the date of grant. These amounts do not necessarily correspond to the actual value recognized or that may be recognized by the named executive officers. |

| (3) | The amounts disclosed represent the aggregate grant date fair value of the option awards granted to our named executive officers during fiscal year 2024 under our 2021 Plan and 2024 Inducement Plan, computed in accordance with FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock options are set forth in Note 8 to our audited financial statements included within our Annual Report on Form 10-K for the year ended December 31, 2024. This amount does not reflect the actual economic value that may be realized by the named executive officer. |

| (4) | The amounts disclosed represent cash incentive compensation earned in 2024, but paid in the beginning of 2025. |

| (5) | The amount shown in this column represent matching payments under our 401(k) Plan, a tax-qualified retirement plan under Section 401(k) of the Internal Revenue Code of 1986, as amended. |

| (6) | Mr. Carter joined the Company in November 2024. |

| (7) | Dr. Brenner joined the Company in January 2024. |

Pension Benefits Our named executive officers did not participate in, or otherwise receive any benefits under, any defined benefit pension sponsored by us during the fiscal year ended December 31, 2024. Nonqualified Deferred Compensation Our named executive officers did not participate in, or earn